Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

Thumbnail

Medicare for all studies agree universal healthcare will lower costs

An analysis of 22 single-payer healthcare plans have nearly all come to the same conclusion: Universal healthcare will lower costs either in the first year or within the first several years.

Thumbnail

NAACOS wants more details, changes to direct contracting payments

Members of the nation’s largest association for accountable care organizations have asked CMS to make some suggested changes to the new direct contracting payment models and release additional details. Not doing so could “derail” the new payment reform, according to NAACOS.

Thumbnail

Coronavirus spread puts medicines at shortage risk

The novel coronavirus originating from China has continued to spread around the world and has increased the risk of drug shortages in the U.S. as a result of dependence on Chinese drug ingredients.

Thumbnail

Mednax gets the axe from UnitedHealth Group’s network

UnitedHealth Group, which owns the nation’s largest health insurance provider UnitedHealthcare, has parted ways with physician staffing firm Mednax, and cut the company from its in-network providers.

Thumbnail

Hip and knee bundles may receive 3-year extension

The Comprehensive Care for Joint Replacement Model, which covers hip and knee joint replacement bundled payments, could see a three-year extension, CMS announced in a proposed rule.

Thumbnail

Oscar Health introduces $3 monthly drug program

Oscar Health has introduced a new drug formulary that will limit the cost for patients to just $3 per month for a supply of commonly used medicines, including insulin.

Thumbnail

Private equity continues to snap up physician groups

Private equity firms are continuing their investments in physician practices, scooping up 355 acquisitions from 2013 to 2016, according to a new study published in JAMA.

Thumbnail

Hedge funds distance themselves from Purdue Pharma

The troubles of Purdue Pharma, the maker of the opioid OxyContin, have led two hedge funds to cut ties with the company as legal consequences from the national opioid abuse and overdose epidemic continue to play out.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup